Evidence map›Paper›PMID 39189933›Full record

ArticleAging2024

Mechanistic study of PD-L1 regulation of metastatic proliferation in non-small cell lung cancer through modulation of IRE1α/XBP-1 signaling pathway in tumor-associated macrophages.

Yi Wang, Lei Yang, Zezheng Liang, Ming Liu

Abstract read
In one paragraph

Article in Aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yi WangDepartment of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Lei YangDepartment of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Zezheng LiangDepartment of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Ming LiuDepartment of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the related research of PD-L1 in IRE1α/XBP-1 signaling pathway on non-small cell lung cancer.

methodsThe tumor model of mice was established and divided into four groups; after successful modeling, the tumor tissue of mice was removed for subsequent experiments; the bought THP-1 cells were grouped into four different groups, a control group, nivolumab intervention group, IRE1α inhibition group, and nivolumab intervention + IRE1α inhibition group; after co-culture of the four groups of THP-1 cells with A549, THP-1 cell protein levels in the four groups were analyzed using Western blot; A549 cell migration, invasion and proliferation were assessed using the scratch assay, Transwell method, monoclonal experiment and CCK-8 method.

results

conclusionPD-L1 is capable of controlling metastatic and proliferative potential of NSCLC by the way of the modification of IRE1α/XBP-1 signaling in tumor-associated macrophages.

Indexed as

B7-H1 AntigenCarcinoma, Non-Small-Cell LungCell ProliferationEndoribonucleasesLung NeoplasmsProtein Serine-Threonine KinasesSignal TransductionTumor-Associated MacrophagesX-Box Binding Protein 1A549 CellsAnimalsCell MovementHumansMiceTHP-1 CellsB7-H1 AntigenCD274 protein, humanEndoribonucleasesERN1 protein, humanProtein Serine-Threonine KinasesX-Box Binding Protein 1XBP1 protein, humanIRE1α/XBP-1 signaling pathwaymacrophagenivolumabnon-small cell lung cancerPD-L1P-STAT3

Identifiers

PMID39189933
PMCPMC11386930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.